Avalo Therapeutics Inc (AVTX) — Cash Flow-to-Debt Ratio
Avalo Therapeutics Inc (AVTX) has a Cash Flow-to-Debt Ratio of -0.49x as of September 2025, meaning its operating cash flow of $-16.36 Million could theoretically repay 0% of its total liabilities ($33.55 Million) in one year. See Avalo Therapeutics Inc free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Avalo Therapeutics Inc Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Avalo Therapeutics Inc across 13 annual periods. Also explore net asset growth rate of Avalo Therapeutics Inc to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Avalo Therapeutics Inc (2012–2024)
Year-by-year debt coverage analysis for Avalo Therapeutics Inc. For market capitalisation and broader financial context, see Avalo Therapeutics Inc market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.77x | $-49.06 Million | $17.70 Million | ▼ -23.7% |
| 2023 | -2.24x | $-30.68 Million | $13.69 Million | ▼ -271.0% |
| 2022 | -0.60x | $-26.75 Million | $44.28 Million | ▲ +51.3% |
| 2021 | -1.24x | $-70.89 Million | $57.13 Million | ▲ +41.3% |
| 2020 | -2.11x | $-40.54 Million | $19.19 Million | ▼ -66.8% |
| 2019 | -1.27x | $-19.13 Million | $15.11 Million | ▼ -1897.1% |
| 2018 | -0.06x | $-3.13 Million | $49.34 Million | ▼ -107.7% |
| 2017 | 0.82x | $12.52 Million | $15.26 Million | ▲ +131.3% |
| 2016 | -2.62x | $-14.57 Million | $5.56 Million | ▼ -121.0% |
| 2015 | -1.19x | $-10.16 Million | $8.57 Million | ▼ -195.2% |
| 2014 | -0.40x | $-15.52 Million | $38.65 Million | ▲ +19.9% |
| 2013 | -0.50x | $-11.49 Million | $22.92 Million | ▲ +91.7% |
| 2012 | -6.02x | $-9.29 Million | $1.54 Million | — |